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Activation of the immune coagulation system has been implicated in the pathogenesis of liver injury follow-
ing infection of inbred mice with murine hepatitis virus strain 3 (MHV-3). Following MHV-3 infection, macro-
phages isolated from MHV-3-susceptible and -semisusceptible inbred strains of mice express increased pro-
coagulant activity (PCA), whereas macrophages from resistant strains express no increase in PCA over basal
levels. The PCA induced by MHV-3 is a prothrombinase, encoded by the gene Fgl-2, which encodes a fibrinogen-
like protein (musfiblp). In this study, MHV-3-resistant A/J mice treated with methylprednisolone prior to infec-
tion with MHV-3 developed elevated levels of alanine aminotransferase in serum and died within 10 days of
infection, with histological findings of fulminant hepatitis. In vitro, macrophages isolated from A/J mice and
pretreated with methylprednisolone produced a marked increase in functional PCA following infection with
MHV-3. The PCA was shown to be a prothrombinase by its ability to cleave 125I-prothrombin. Northern blot
analysis of RNA transcripts from these macrophages demonstrated increased transcription of the Fgl-2 gene
relative to that in macrophages which had not been pretreated with methylprednisolone prior to MHV-3 infec-
tion. Methylprednisolone pretreatment of MHV-3-infected macrophages stabilized the Fgl-2 mRNA. Thus, loss
of resistance to MHV-3 secondary to methylprednisolone therapy is associated with increased transcription
and stability of Fgl-2 mRNA resulting in expression of the Fgl-2 gene product, musfiblp. These results provide
further insight into mechanisms of PCA regulation in response to MHV-3 infection in inbred strains of mice.
Fulminant viral hepatitis is a rapidly progressive disease
which is associated with high mortality (18). Although the
pathogenesis is unknown, there is evidence supporting a role
for activation of the immune coagulation system and secondary
microcirculatory disturbances with resultant intravascular throm-
bosis in the liver (4, 17, 26–28). Agents which interfere with
activation of the classical or immune coagulation system have
been shown to be beneficial in the setting of fulminant hepa-
titis (1, 32, 37).
Infection of inbred mice with murine hepatitis virus strain 3
(MHV-3), a member of the coronavirus family, produces a
strain-dependent spectrum of liver disease which has been
utilized as a model of fulminant hepatitis (19, 24, 43). Follow-
ing infection with MHV-3, BALB/cJ and C57BL/6J mice de-
velop a fatal hepatitis characterized histologically by sinusoidal
thrombosis and hepatocellular necrosis, similar to that seen in
humans with fulminant viral hepatitis, whereas A/J mice de-
velop neither histological nor biochemical evidence of liver
injury (19, 21, 25). Three lines of evidence suggest that activa-
tion of the immune coagulation system by MHV-3, as evi-
denced by increased macrophage/monocyte procoagulant ac-
tivity (PCA), participates in the disease process in MHV-3-
related hepatitis. First, induction of monocyte/macrophage PCA
during MHV-3 infection correlates with the severity of liver
injury (7, 20). Second, there is a genetic linkage between induc-
tion of PCA in response to MHV-3 and susceptibility to liver
disease (8). Finally, treatment of susceptible mice with a mono-
clonal antibody to MHV-3-induced prothrombinase prevents
the development of MHV-3-related fulminant hepatitis (22).
We recently reported the molecular cloning and sequencing
of a cDNA isolated from a library prepared from macrophages
which had been infected with MHV-3 (29). The sequence of
this cDNA is essentially identical to a previously described se-
quence corresponding to a gene encoding a mouse fibrinogen-
like protein (musfiblp) (16). Recently, this gene has been re-
named Fgl-2. In macrophages, Fgl-2-specific mRNA is not
normally expressed. However, following infection, expression
can be detected in macrophages derived from resistant as well
as susceptible strains of mice, with expression of this gene
occurring earlier and in significantly greater amounts in mac-
rophages derived from susceptible strains (29). Transfection
of the RAW 264.7 cell line, a BALB/cJ macrophage continu-
ous cell line which does not express PCA following exposure to
MHV-3, with a cDNA containing the entire coding region of
Fgl-2 resulted in expression of functional PCA with prothrom-
binase activity following infection, confirming that Fgl-2 is the
gene encoding MHV-3-induced PCA (29).
It has been demonstrated that a loss of resistance and 100%
mortality occur in mice from resistant strains which are treated
with corticosteroids prior to infection with MHV (5, 11). How-
ever, the mechanism for this loss of resistance is not known.
The current studies were initiated to determine whether the
loss of resistance following corticosteroid therapy is associated
with induction of Fgl-2 gene transcription and PCA expression
in resistant A/J mice.
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MATERIALS AND METHODS
Mice. Female A/J mice aged 6 to 8 weeks were purchased from Jackson
Laboratories (Bar Harbor, Maine), housed in the animal colony at the University
of Toronto, and fed a standard chow diet and water ad libitum prior to and
during studies. Animals were maintained in microisolation cages, and serologic
tests for evidence of prior MHV infection were consistently negative.
Cells and virus. The origin and growth of 17CL1, DBT, and L2 cells have been
described previously (14, 33, 39). MHV-3 was obtained from the American Type
Culture Collection, Rockville, Md., and plaque purified on monolayers of DBT
cells. Stock virus was grown to a titer of 4.8 3 107 PFU/ml in 17CL1 cells, har-
vested by one cycle of freeze-thawing, and clarified by centrifugation at 4,500 3
g for 1 h at 48C. Viral titers were determined on monolayers of L2 cells in a
standard plaque assay (23, 39).
Chemicals. Methylprednisolone sodium succinate (Solu-medrol; Upjohn Co.,
Don Mills, Ontario, Canada) used in the in vitro studies was dissolved in RPMI
1640 (Gibco Laboratories, Grand Island, N.Y.) at concentrations of 3.75 to 150
mg/ml, while methylprednisolone used in the in vivo studies was dissolved in
sterile distilled water at a standard concentration of 10 mg/ml. All samples were
filter sterilized with Millex-GS 0.22-mm-pore-size filter units (Millipore Products,
Bedford, Mass.) and stored at 48C until use.
Peritoneal macrophages. Peritoneal macrophages, harvested from A/J mice 4
days after intraperitoneal administration of 1.5 ml of 3% aged Brewer’s thiogly-
colate pH 6.9 (Difco Laboratories, Detroit, Mich.), were suspended in RPMI
1640 supplemented with 2 mM glutamine (Sigma Chemical Co., St. Louis, Mo.)
(RPMI 0) as previously described (38). Cell suspensions contained greater than
95% macrophages as determined by morphology and nonspecific esterase stain-
ing, with viability exceeding 98% by trypan blue exclusion. Viability was not
affected by incubation with up to 120 mg of methylprednisolone per ml (data not
shown).
Biochemistry. Serum was analyzed quantitatively for alanine aminotransferase
activity with a Worthington Statzyme GPT kit obtained from Cooper Biomedical,
Inc., Malvern, Pa. (13).
Histology. Liver tissue which had been fixed by immersion in 10% formalin in
0.1 M phosphate buffer, pH 7.4, was dehydrated in graded alcohols and xylene
and embedded in paraffin. Sections were cut and stained with Harris’ hematox-
ylin and counterstained with eosin Y. The sections were subsequently washed
with distilled water, dehydrated in graded alcohols and xylene, and mounted with
Permount. Tissue sections were assessed for the presence of necrosis and in-
flammatory cell infiltration as previously described (22).
Immunofluorescence. Samples of liver tissue were snap frozen in liquid nitro-
gen and cut into sections approximately 4 mm thick. Sections were fixed for 5 min
in acetone and air dried for 2 h, following which unoccupied sites were blocked
with 5% horse serum in phosphate-buffered saline (PBS), pH 7.4. Following 2 h
of incubation, samples were stained for 1 h with 3D4.3, an antiprothrombinase
monoclonal antibody recently isolated in our laboratory (13), and conjugated
with fluorescein isothiocyanate (Sigma Chemical Co.) as previously described
(22, 40). The liver tissue samples were then washed three times, mounted in 90%
glycerol in PBS, and examined on a phase-epifluorescence microscope equipped
with a 403 Fluotar objective (E. Leitz, Inc., Rockleigh, N.J.).
PCA studies.Macrophages, suspended at a concentration of 106 cells per ml in
RPMI 1640, were treated with either 0 or 100 mg of methylprednisolone per ml
and 30 min later were infected with MHV-3 at a multiplicity of infection of 1.0.
Similarly, macrophages were pretreated with either 0 or 100 mg of methylpred-
nisolone per ml without being infected with MHV-3. Following incubation
periods of up to 8 h, cells underwent a single freeze-thaw cycle and total content
PCA was assayed by determining the ability of the suspensions to accelerate the
spontaneous clotting time of normal recalcified human platelet-poor plasma as
previously described (1). Results were quantitated by comparison with serial
dilutions of standard rabbit brain thromboplastin (Sigma Chemical Co.). Me-
dium and reagents were without procoagulant activity.
Prothrombin cleavage assays. Peritoneal macrophages, suspended at 4.03 106
cells per ml in RPMI 1640, were pretreated with 0 or 100 mg of methylpred-
nisolone per ml and, 30 min later, infected with MHV-3 at a multiplicity of
infection of 1.0. Following incubations of 6 h, 0.05-ml aliquots of these macro-
phages were incubated for 1 h at 378C with 0.01-ml aliquots of 25 mM CaCl2 and
0.01 ml of 100 nM 125I-prothrombin which had been prepared as previously
described (10, 35). Human factor Xa in the presence of Russell’s viper venom
was used as a positive control for 125I-prothrombin cleavage. Reactions were
terminated by addition of EDTA and sodium dodecyl sulfate (SDS) to achieve a
1% concentration, and the products were analyzed by electrophoresis on 10%
polyacrylamide–0.1% SDS gels followed by fixing and drying of the gel and,
finally, autoradiography (10, 35).
Northern (RNA) blot analysis. Macrophages were harvested from A/J mice
and suspended at a concentration of 2.0 3 106 cells per ml in RPMI 1640,
preincubated for 30 min in the presence or absence of 100 mg of methylpred-
nisolone per ml, and infected with MHV-3 at a multiplicity of infection of 1.0.
Following incubations of up to 6 h, macrophages were washed two times with
cold 0.1 M PBS, pH 7.2, and pelleted in polypropylene tubes (17 by 100 mm;
Falcon, Becton Dickinson Labware, Lincoln Park, N.J.). Total cellular RNA was
isolated by using 8 M guanidine hydrochloride (9). RNA was resolved in a 1%
agarose gel containing formaldehyde and transferred onto a nitrocellulose mem-
brane (Bio-Rad, Oakville, Ontario, Canada).
A 1.3-kb Fgl-2 cDNA was excised, separated on an agarose gel, and purified
(29). The probe was labelled by using a random-primer DNA-labelling system
(T7QuickPrime Kit; Pharmacia Inc., Montreal, Quebec, Canada) with [a-32P]
dCTP (specific activity,.3,000 Ci/mmol; Amersham, Mississauga, Ontario, Can-
ada). Membranes were prehybridized for 6 h at 428C in a solution containing
50% formamide, 53 Denhardt’s solution, 0.1% SDS, 100 mg of denatured
salmon sperm DNA per ml, and 53 SSPE (13 SSPE is 0.18 M NaCl, 10 mM
NaH2PO4, and 1 mM EDTA [pH 7.7]) buffer. Hybridization was subsequently
carried out overnight at 428C in the same solution with the addition of radiola-
belled probe. The membranes were then washed twice for 15 min each time at
room temperature with 53 SSPE–0.5% SDS; this was followed by two additional
washes each for 15 min at 378C with 13 SSPE–0.5% SDS and finally three
washes for 15 min each at 658C with 0.13 SSPE–1.0% SDS. Membranes were
dried and exposed to Kodak XAR-5 film with intensifying screens for 24 h at
2708C. To confirm that equivalent amounts of RNA were loaded in each lane,
membranes were probed with a human glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH) cDNA probe (41).
RNA stability studies. Peritoneal macrophages, suspended at a concentration
of 2.0 3 106 cells per ml in RPMI 0, were infected with MHV-3 at a multiplicity
of infection of 1.0 following a 30-min preincubation in the presence or absence
of 100 mg of methylprednisolone per ml. Following a 6-h incubation, actinomycin
D (10 mg/ml), an inhibitor of gene transcription, was added, and after further
incubation for up to 6 h, samples were harvested, washed twice in ice-cold 0.1 M
PBS (pH 7.2), and pelleted in polypropylene tubes (17 by 100 mm). Northern
blot analysis was carried out as described above. Quantitation was performed
with a Betagen scanner (29).
Statistical analysis. Data are expressed as means 6 standard deviations.
Statistical analysis utilized Student’s t test or analysis of variance when appro-
priate. A P value of 0.05 or less was considered statistically significant.
RESULTS
In vitro studies. (i) Effect of methylprednisolone pretreat-
ment on induction of PCA in response to MHV-3 infection in
vitro. A/J macrophages infected with MHV-3 in vitro without
prior treatment with methylprednisolone or treated with meth-
ylprednisolone and not infected with MHV-3 expressed only
baseline levels of PCA, similar to levels expressed by macro-
phages which were neither treated with methylprednisolone
nor infected with MHV-3. However, macrophages which were
pretreated for 30 min with 100 mg of methylprednisolone per
ml prior to MHV-3 infection expressed significantly increased
levels of PCA, with peak PCA levels of 3,300 6 980 mU/106
macrophages recorded following 6 h of incubation with MHV-
3 (P , 0.05) (Fig. 1).
In subsequent experiments, macrophages, suspended at a
concentration of 106 cells per ml, were treated with increasing
concentrations of methylprednisolone prior to infection with
MHV-3 and incubated for 6 h. Pretreatment of macrophages
with methylprednisolone resulted in a dose-dependent aug-
mentation of the PCA response to MHV-3. Pretreatment for
30 min with methylprednisolone at a concentration equal to or
greater than 3.75 mg/ml followed by incubation for 6 h with
MHV-3 resulted in an augmented macrophage PCA response.
At a concentration of methylprednisolone of 3.75 mg/ml, the
PCA response was 1,695 6 378 mU/ml, compared with 135 6
40 mU/ml in macrophages incubated with MHV-3 without pre-
treatment with methylprednisolone (P , 0.05). With increas-
ing concentrations of methylprednisolone, the PCA response
to MHV-3 continued to rise to a maximal PCA response of
3,350 6 88 mU/ml following treatment with 120 mg of methyl-
prednisolone per ml (Fig. 2).
(ii) In vitro MHV-3 replication. Viral titers were determined
in peritoneal macrophages which were pretreated for 30 min
with 0, 30, 60, or 100 mg of methylprednisolone per ml and
incubated for up to 48 h following infection with MHV-3.
Methylprednisolone pretreatment of macrophages had no ef-
fect on MHV-3 replication in these cells at all time points
studied (data not shown).
(iii) Prothrombin cleavage assays.Macrophages which were
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neither treated with methylprednisolone nor infected with
MHV-3 did not exhibit prothrombinase activity, as demon-
strated by the inability to cleave 125I-prothrombin. Similarly,
macrophages infected with MHV-3 without being pretreated
with methylprednisolone did not demonstrate induction of pro-
thrombinase activity following incubation for up to 8 h. How-
ever, macrophages which were both treated with methylpred-
nisolone and infected with MHV-3 elaborated prothrombinase
activity as early as 1 h post-MHV-3 infection, which progres-
sively increased, as evidenced by increased 125I-prothrombin
cleavage at 2, 4, 6, and 8 h postinfection with MHV-3. Thus,
only A/J macrophages which were both treated with methyl-
prednisolone and infected with MHV-3 demonstrated pro-
thrombin cleavage or prothrombinase activity (Fig. 3).
(iv) Fgl-2 mRNA expression. No constitutive expression of
Fgl-2 mRNA was seen in uninfected macrophages derived
from A/J mice regardless of methylprednisolone treatment (re-
sults not shown). In contrast, low levels of Fgl-2 RNA were
detected in MHV-3-infected and methylprednisolone-untreat-
ed macrophages within 6 h of incubation with MHV-3. Treat-
ment of A/J-derived macrophages with methylprednisolone for
30 min prior to infection with MHV-3 resulted in an earlier
and markedly increased expression of RNA encoding for Fgl-2.
Transcription of Fgl-2 was detectable as early as after 1 h of
incubation with MHV-3 (Fig. 4). Levels of Fgl-2 mRNA in
macrophages both pretreated with methylprednisolone and in-
fected with MHV-3 reached a peak at 6 h postinfection with a
slight decline at 8 h postinfection. Thus, treatment of A/J macro-
phages with methylprednisolone prior to infection with MHV-
3 results in increased accumulation of Fgl-2 mRNA following
infection with MHV-3.
(v) Fgl-2 mRNA stability assays. To determine whether the
increase in Fgl-2mRNA levels observed after administration of
corticosteroids was at least in part due to a posttranscriptional
mechanism, Fgl-2 mRNA stability studies were carried out.
Following 6 h of incubation with MHV-3, baseline Fgl-2 mRNA
levels were significantly greater in macrophages treated with
methylprednisolone prior to MHV-3 infection than in macro-
phages not pretreated with methylprednisolone. Over the sub-
FIG. 1. Effect of methylprednisolone on induction of PCA in response to
MHV-3 in A/J-derived peritoneal macrophages in vitro. Macrophages pretreated
for 30 min with 100 mg of methylprednisolone per ml were incubated in either the
absence (F) or presence () of MHV-3. Two additional groups, not treated with
methylprednisolone, either were not (E) or were () infected with MHV-3.
Results represent PCA expression following 0, 2, 4, 6, and 8 h of incubation and
are the arithmetic means 6 standard deviations from three studies repeated in
triplicate. p, statistical significance (P , 0.05) versus macrophages neither
treated with methylprednisolone nor infected with MHV-3.
FIG. 2. Effects of increasing concentrations of methylprednisolone on induction of PCA by MHV-3 in A/J-derived macrophages. Macrophages were pretreated for
30 min with methylprednisolone (MP) and infected with MHV-3. PCA expression was determined following 6 h of incubation. Results represent the means 6 standard
deviations from three studies repeated in triplicate. p, statistical significance (P , 0.05) versus macrophages neither treated with methylprednisolone nor infected with
MHV-3 (control).
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sequent 6 h, following treatment with actinomycin D, Fgl-2
mRNA levels decayed more rapidly in the MHV-3-infected
and methylprednisolone-untreated macrophages than in the
MHV-3-infected and methylprednisolone-treated macrophages
(Fig. 5). Quantitation by beta scanning indicated that methyl-
prednisolone pretreatment stabilized Fgl-2 mRNA, with great-
er than 60% activity seen at 6 h, when less than 5% of initial
PCA activity was seen in RNA extracted from macrophages
which had been infected with MHV-3 but not pretreated
with methylprednisolone. Thus, the increased accumulation of
Fgl-2 mRNA in response to MHV-3 after corticosteroid treat-
ment is at least in part attributable to increased stability of the
mRNA.
In vivo studies. (i) Survival. A/J mice infected with 106 PFU
of MHV-3 demonstrated no subjective or objective evidence of
disease, and all mice survived for 14 days, at which time they
were sacrificed. Histologic or gross examination revealed no
signs of liver injury. In contrast, A/J mice which had been treat-
ed with methylprednisolone at a concentration of 500 mg/kg of
body weight per day beginning 3 days prior to infection with
106 PFU of MHV-3 developed clinical signs of disease by day
2 postinfection, characterized by ruffled fur and lethargy. By
day 3, oral intake was markedly reduced; by day 4, mice in
this group began to die; and by day 10 postinfection, all mice
had died (Fig. 6). Postmortem examinations demonstrated
pale mottled livers in these mice, consistent with fulminant
MHV-3 hepatitis. A/J control mice which received neither
methylprednisolone nor MHV-3 or received methylpredni-
solone alone at concentrations as high as 500 mg/kg/day for
14 days all survived and demonstrated no histological or
biochemical liver abnormalities.
(ii) Viral replication. The patterns of viral replication in the
first 6 days of infection were similar in liver tissue recovered
from mice infected with MHV-3 and either treated or not treat-
ed with methylprednisolone. Viral replication could first be
detected by day 3 postinfection, with peak viral titers reached
on day 6. By day 9, when viral replication was no longer de-
tected in liver tissue obtained fromMHV-3-infected and meth-
ylprednisolone-untreated mice, viral titers in the surviving
methylprednisolone-treated and MHV-3-infected mice re-
mained at high levels, which persisted until the death of the
animals (Fig. 7).
FIG. 3. Effect of methylprednisolone on induction of prothrombinase by
MHV-3 in A/J-derived peritoneal macrophages. Macrophages, either pretreated
or not pretreated for 30 min with methylprednisolone at 100 mg/ml, were infected
with MHV-3 and incubated for up to 8 h. Macrophages were then incubated for
60 min with 125I-prothrombin and 25 mM CaCl2. SDS and EDTA were added,
and the samples were electrophoresed on an SDS–10% polyacrylamide slab gel
with results displayed by autoradiography. Lane 1, 125I-prothrombin incubated
with RPMI 1640 (negative control); lane 2, 125I-prothrombin incubated with
human factor Xa and Russell’s viper venom (positive control); lanes 3 to 7, 125I-
prothrombin incubated withmacrophages which were not pretreated withmethyl-
prednisolone but were incubated with MHV-3 for 1 h (lane 3), 2 h (lane 4), 4 h
(lane 5), 6 h (lane 6), or 8 h (lane 7); lanes 8 to 12, 125I-prothrombin incubated with
macrophages which were pretreated with methylprednisolone and incubated with
MHV-3 for 1 h (lane 8), 2 h (lane 9), 4 h (lane 10), 6 h (lane 11), or 8 h (lane 12).
FIG. 4. Effect of methylprednisolone on transcription of Fgl-2 in A/J-derived macrophages stimulated with MHV-3. Ten micrograms of total RNA per lane, isolated
from A/J-derived peritoneal macrophages which were not (A) or were (B) pretreated for 30 min with methylprednisolone and infected with MHV-3 for 0, 1, 2, 4, or
8 h, was hybridized with a 1.3-kb cDNA probe for Fgl-2. A GAPDH cDNA probe was used to ensure equal loading of each lane.
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(iii) Biochemistry. In MHV-3-infected but methylpredniso-
lone-untreated A/J mice, no increase in alanine aminotransfer-
ase activity, a marker of hepatocellular necrosis, was seen, simi-
lar to results in methylprednisolone-untreated and MHV-
3-uninfected mice. In contrast, marked increases in serum
alanine aminotransferase were noted in methylprednisolone-
treated and MHV-3-infected A/J mice within 3 days of infec-
tion. Maximal alanine aminotransferase levels of 740 6 145
IU/liter were seen on day 6 postinfection and did not sig-
nificantly change until time of death of these animals by day 10.
(iv) Histology. Livers obtained from control mice or mice
treated with methylprednisolone at 500 mg/kg/day for 14 days
showed normal architecture. Similarly, no histological evidence
of hepatocellular injury was seen in A/J mice infected withMHV-
3 and which had not received methylprednisolone. In contrast, in
mice treated with methylprednisolone and infected with MHV-3,
histologic evidence of hepatocellular necrosis associated with por-
tal and periportal infiltrations of mononuclear and polymorpho-
nuclear cells was observed by day 3 following infection with
MHV-3 and progressed to a marked coagulative necrosis by day
6 (Fig. 8).
(v) Immunofluorescence. By direct immunofluorescence stain-
ing, expression of PCA was detected in liver tissue from the
methylprednisolone-treated and MHV-3-infected mice in ar-
eas of inflammation as well as in hepatic sinusoids adjacent to
areas of hepatic necrosis within 3 days of viral infection. In the
sinusoids, PCA expression localized primarily to endothelial
and Kuppfer cells. PCA expression was more pronounced in
livers harvested from methylprednisolone-treated and MHV-
3-infected mice at 6 and 9 days postinfection (Fig. 9). Expres-
sion of PCA was not detected by immunofluorescence staining
in the livers of methylprednisolone-untreated and MHV-3-
infected A/J mice or control uninfected A/J mice which either
were or were not treated with methylprednisolone.
DISCUSSION
MHV-3 infection in inbred strains of mice serves as a model
to study the pathogenesis of virally induced liver injury. De-
spite similar patterns of growth of virus, BALB/cJ and A/J mice
FIG. 6. The effects of methylprednisolone on survival in A/J mice infected
with MHV-3. A/J mice (10 in each group), pretreated for 3 days with either 500
mg of methylprednisolone per day (F) or normal saline (E) injected intraperi-
toneally, were infected with 106 PFU of MHV-3. Treatment with either meth-
ylprednisolone or normal saline was continued following infection with MHV-3,
and survival was studied for 14 days postinfection.
FIG. 5. Methylpredisolone increases stability of Fgl-2 mRNA. (A) Ten micrograms of total RNA per lane was isolated from A/J-derived peritoneal macrophages
which either were not or were pretreated for 30 min with 100 mg of methylprednisolone (MP) per ml, infected with MHV-3 for 6 h, and then incubated with actinomycin
D (10 mg/ml), an inhibitor of gene transcription, for 0, 2, 4, or 6 h. RNA was hybridized with a 1.3-kb cDNA probe for Fgl-2. A GAPDH cDNA probe was used to
ensure equal loading of each lane. (B) Quantification of Fgl-2 mRNA by a Betagen scanner. 3, GAPDH; E, Fgl-2 plus MP; h, Fgl-2.
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demonstrate markedly different responses to MHV-3 (19, 24,
43). Following infection, A/J mice develop neither clinical, his-
tological, nor biochemical evidence of liver injury; clear the
virus by 10 to 14 days; and survive. In contrast, BALB/cJ mice
develop severe hepatitis characterized by neutrophil and mono-
nuclear cell infiltrates of the hepatic parenchyma, sinusoidal
fibrin deposition, and coagulative hepatocellular necrosis (19,
21, 25). Thus, factors other than viral replication must be im-
portant in the pathogenesis of MHV-3-induced liver disease.
Resistance to MHV-3 may be dependent upon immune de-
fense mechanisms either alone or in combination with innate
macrophage factors alone or in combination with the absence
of functional cellular receptors (2).
We have previously demonstrated that MHV-3 causes in-
duction of a unique procoagulant (PCA) in murine cells of the
monocyte/macrophage line in a strain-dependent pattern (8,
20). Synthesis of PCA correlates with disease susceptibility and
is responsible for the coagulative liver necrosis seen in suscep-
tible mice following MHV-3 infection (10, 20, 25). Supportive
evidence for the role of PCA in the pathogenesis of MHV-3-
related liver disease has been derived from recent studies in
which susceptible mice which were treated with a high-titer
neutralizing antibody to the MHV-3-induced PCA were pro-
tected from MHV-3-related liver injury in vivo (22). Together,
these studies support the concept that activation of the im-
mune coagulation system as evidenced by induction of PCA
synthesis plays an important role in the pathogenesis of MHV-
3-related liver disease.
We have recently identified the gene, Fgl-2, responsible for
production of PCA in murine macrophages infected with
MHV-3 and have shown that this gene is located on mouse
chromosome 5 (29, 31). In macrophages derived from suscep-
tible BALB/cJ mice, expression of Fgl-2 mRNA was detected
within 3 h of MHV-3 infection, peaked at 6 h, and returned to
baseline by 24 h. By comparison, expression of Fgl-2 RNA
transcripts in macrophages derived from resistant A/J mice was
markedly delayed and 120-fold lower than that seen in
BALB/cJ mice (29). Despite transcription of small amounts of
Fgl-2 mRNA, no functional expression of the gene product of
Fgl-2 (PCA) was seen in macrophages derived from A/J mice
in response to MHV-3 (29). In contrast, infection of macro-
phages derived from susceptible BALB/cJ mice resulted in
rapid expression of functional PCA within 2 h of infection
which persisted for 24 h (29). The data reported here demon-
FIG. 7. Effect of methylprednisolone on intrahepatic viral replication in A/J
mice infected with MHV-3. A/J mice, pretreated with either methylprednisolone
(500 mg/kg/day) (F) or normal saline (E) for 3 days, were infected with 106 PFU
of MHV-3. Treatment with normal saline or methylprednisolone was continued
following MHV-3 infection. Results represent the arithmetic means 6 standard
deviations of viral titers in livers harvested from three mice at each time point.
p, statistical significance (P , 0.05) versus methylprednisolone-untreated and
MHV-3-infected mice.
FIG. 8. Effects of methylprednisolone on liver histology in A/J mice infected with MHV-3. Liver tissue was obtained from A/J mice infected with 106 PFU of MHV-3
following 3 days of pretreatment with either methylprednisolone (500 mg/kg/day) or normal saline with continuation of therapy following MHV-3 infection. (A) Liver
tissue obtained at sacrifice on day 14 from an A/J mouse infected with MHV-3 and treated with normal saline prior to and following MHV-3 infection. No histological
abnormalities are present. (B) Liver tissue obtained on day 7 post-MHV-3 infection from an A/J mouse that was treated with methylprednisolone prior to and following
infection with MHV-3. Extensive hepatocellular necrosis associated with inflammatory cell infiltrate is present and is consistent with fulminant acute hepatitis.
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strate that the coding sequence of the prothrombinase (Fgl-2)
must be intact in A/J mice. This suggests that differences in
expression of the gene following MHV-3 infection in BALB/cJ
and A/J mice must reside in part in differences in the signal
transduction pathway, differences in the promoter region,
and/or differences in mRNA degradation.
In the current studies, we have confirmed that treatment of
A/J mice with methylprednisolone results in a loss of resistance
to MHV-3. All A/J mice treated with methylprednisolone and
infected with MHV-3 died within 10 days of infection. Post-
mortem findings were consistent with acute hepatitis charac-
terized by coagulative hepatic necrosis. Immunofluorescence
studies, using a monoclonal antibody to the MHV-3-induced
prothrombinase (3D4.3), demonstrated PCA in liver tissue
harvested from mice which had been pretreated with methyl-
prednisolone and infected with MHV-3 in areas of hepatic
necrosis as well as in hepatic sinusoids adjacent to areas of
hepatic necrosis within 48 h of infection with MHV-3. In vitro,
macrophages derived from A/J mice which were pretreated
with methylprednisolone and infected with MHV-3 expressed
increased levels of functional PCA, as determined by a single-
stage clotting assay. Prothrombin cleavage studies confirmed
that this increased PCA was a direct prothrombinase. The pro-
thrombin cleavage activity was associated with increased and
earlier transcription of the Fgl-2 gene. In addition, RNA sta-
bility studies demonstrated that methylprednisolone resulted
in increased stability of the Fgl-2 RNA, suggesting that a sec-
ond mechanism underlying corticosteroid-related up-regula-
tion of Fgl-2 expression was posttranscriptional stabilization of
an otherwise labile mRNA.
Regulation of mRNA turnover plays an important role in
modulating gene expression and has been demonstrated as
being important in the adjustment of expression of cytokines,
transcription factors, and proto-oncogenes (15, 34, 36). Many
mRNAs which undergo rapid turnover contain a common se-
quence, AUUUA, which signals for rapid degradation (36).
We have found one such sequence in the 39 untranslated re-
gion of the Fgl-2 gene cDNA sequence. At present, themechan-
isms responsible for the rapid degradation of the Fgl-2 mRNA
are not known. The AUUUA sequence might direct the nas-
cent Fgl-2 mRNA to a cytoplasmic compartment where rapid
degradation would occur. Alternatively, the sequence may be
recognized by an RNA-binding protein involved in the specific
degradation of transiently expressed RNA sequences (36). Po-
tentially, the synthesis of this RNA-binding protein is inhibited
in the presence of corticosteroids, leading to Fgl-2 stabilization
and, ultimately, PCA expression. Whether these mechanisms
are operative for the Fgl-2 gene remains to be proven.
Recent studies have shown that corticosteroids alter the
T-helper lymphocyte response to antigens from a Th1 to a Th2
response (6, 12, 42). We have shown previously that resistance
to MHV-3 is dependent on a Th1 response and that Th1 lymph-
ocytes derived from resistant mice exposed to MHV-3 inhibit
procoagulant expression in MHV-3-infected macrophages in
vitro and protect susceptible mice from the lethal effects of
MHV-3 in vivo (3). Furthermore, we have now shown that
MHV-3-specific Th2 lymphocytes isolated from susceptible
mice increase the transcription of Fgl-2 by macrophages, and
adoptive transfer of these lymphocytes failed to protect naive
BALB/cJ mice from MHV-3 infection (30). Thus, an addition-
al mechanism for loss of resistance to MHV-3 by corticoste-
roids may be changing of the T-helper response to MHV-3 in
resistant mice from a Th1 to a Th2 response, resulting in aug-
mented Fgl-2 transcription and ultimately procoagulant expres-
sion.
In summary, corticosteroid therapy of MHV-3-resistant A/J
FIG. 9. Effects of methylprednisolone on intrahepatic expression of prothrombinase in mice infected with MHV-3. Immunofluorescence studies were carried out
with liver tissue harvested from MHV-3-infected A/J mice which either were or were not pretreated with 500 mg of methylprednisolone per kg per day beginning 3
days prior to infection with 106 PFU of MHV-3. Sections were stained with 3D4.3, an antiprothrombinase monoclonal antibody, and conjugated with fluorescein
isothiocyanate. (A) Liver tissue harvested at 3 days postinfection from a methylprednisolone-untreated and MHV-3-infected mouse demonstrates no detectable
immunofluorescence, confirming an absence of intrahepatic prothrombinase expression in livers harvested from mice infected with MHV-3 without also being treated
with methylprednisolone. (B) Liver tissue harvested at 3 days postinfection from a methylprednisolone-treated and MHV-3-infected A/J mouse demonstrates
expression of prothrombinase in areas of inflammation as well as in hepatic sinusoids. In sinusoids, fluorescence localized primarily to endothelial and Kuppfer cells.
(C) Liver tissue harvested at 5 days postinfection from a methylprednisolone-treated and MHV-3-infected A/J mouse demonstrates extensive expression of prothrom-
binase in areas of inflammation as well as in hepatic sinusoids adjacent to areas of hepatic necrosis.
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mice is associated with a loss of resistance to MHV-3 and
increased accumulation of the Fgl-2 mRNA associated with
posttranscriptional stabilization of the Fgl-2 mRNA, leading to
expression of the Fgl-2 gene product prothrombinase. These
studies provide further insight into mechanisms of PCA regu-
lation in response to MHV-3 infection in inbred strains of mice
and further define the importance of the Fgl-2 product PCA in
the pathogenesis of MHV-3-induced fulminant liver failure.
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